Non-Hodgkin Lymphoma CAR T Cells: Enhancement on Synnotch Signaling, GLUT1 expression, and PGC1a expression brings Potential Clinical Advancement in Therapy
Pages 97 - 105
Abstract
While prior therapies for malignant solid tumors mostly focused on surgical excision and/or chemotherapy/radiotherapy, it is now feasible to combat cancers via monitoring and manipulating the immune system. Hence, the main purpose of this work is to hypothesize a potential combinational therapy with prospective enhancements to Chimeric Antigen Receptor T cells, a provision of anticipated results in vivo immune compromised Rat model with Non-Hodgkin's Lymphoma. This study, based on previously done research, it suggests the inclusion of Synnotch Receptor, which can manage T cell exhaustion and alter antigen recognition by on/off switching the receptors, particularly adjusting for CD19 and supplementary CD22, CD20, and CD30. In addition to Synnotch, this work suggests that PGC1a and GLUT 1 be upregulated to deal with the problem of poor persistence in the tumor microenvironment, monitored by western blot and flow cytometry during experiments, and in addition, with the application of GM-CSF for tackling cytokine release syndrome.
References
[1]
PDQ® Adult Treatment Editorial Board. PDQ Adult Non-Hodgkin Lymphoma Treatment. Bethesda, MD: National Cancer Institute. Updated December 10, 2021. Available at: https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq. Accessed <December 10, 2021>. [ 26389337]
[2]
Srivastava, Shivani “Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.” Cancer cell vol. 35, 3, 2019: 489-503.e8.
[3]
Hyrenius-Wittsten, Axel, Yang Su, Minhee Park, Julie M. Garcia, Josef Alavi, Nathaniel Perry, Garrett Montgomery, Bin Liu, and Kole T. Roybal. "SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mice models." Science translational medicine 13, no. 591, 2021: eabd8836.
[4]
Rostamian, Hosein, “Mitochondria as Playmakers of Car T-Cell Fate and Longevity.” Cancer Immunology Research, vol. 9, no. 8, 2021, pp. 856–861., https://doi.org/10.1158/2326-6066.cir-21-0110.
[5]
Ying, Zhitao, Ting He, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie "Parallel comparison of 4-1BB or CD28 co-stimulated CD19-targeted CAR-T cells for B cell non-Hodgkin's lymphoma." Molecular Therapy-Oncolytics 15. 2019: 60-68.
[6]
Ying Zhitao, Xue F. Huang, Xiaoyu Xiang, Yanling Liu, Xi Kang, Yuqin Song, Xiaokai Guo "A safe and potent anti-CD19 CAR T cell therapy." Nature medicine 25, no. 6, 2019: 947-953.
[7]
Sozen, Berna, Saffet Ozturk, Aylin Yaba, and Necdet Demir. "The p38 MAPK signaling pathway is required for glucose metabolism, lineage specification and embryo survival during mouse preimplantation development." Mechanisms of development 138, 2015: 375-398.
[8]
Choi, Beom K “4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation.” Cellular & molecular immunology vol. 14, 9, 2017: 748-757.
[9]
Morsut, Leonardo, "Engineering customized cell sensing and response behaviors using synthetic notch receptors." Cell 164.4, 2016: 780-791.
[10]
Demaret, J, Varlet, P, Traut, J, Monitoring CAR T-cells using flow cytometry. Cytometry. 2021; 100: 218– 224. https://doi.org/10.1002/cyto.b.21941
[11]
Nair, Anroop B, and Shery Jacob. “A simple practice guide for dose conversion between animals and human.” Journal of basic and clinical pharmacy vol. 7, 2, 2016: 27-31.
[12]
Lee, Jienny, Eun-Na Lee, Eun-Young Kim, Hae-Jung Park, Chi-Young Chang, Da-Yeon Jung, Su-Young Choi "Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease." Immunology letters 101, no. 2, 2005: 210-216.\
[13]
Rocha, Cristiano Krings “A rare case of t (11;22) in a mantle cell lymphoma like B-cell neoplasia resulting in a fusion of IGL and CCND1: case report.” Molecular cytogenetics vol. 4,1 8. 1 Apr., 2011.
[14]
Sterner, Rosalie M “GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.” Blood vol. 133, 7, 2019: 697-709.
[15]
Ali Hosseini Rad, S. M., Aarati Poudel, Grace Min Yi Tan, and Alexander D. McLellan. "Optimisation of Tet-On inducible systems for Sleeping Beauty-based chimeric antigen receptor (CAR) applications." Scientific reports 10, no. 1, 2020: 1-12.
[16]
Chester, Cariad, Miguel F. Sanmamed, Jun Wang, and Ignacio Melero. "Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies." Blood, The Journal of the American Society of Hematology 131, no. 1, 2018: 49-57.
[17]
David M. Barrett, Nathan Singh, Ted J. Hofmann, Zachary Gershenson, Stephan A. Grupp; Interleukin 6 Is Not Made By Chimeric Antigen Receptor T Cells and Does Not Impact Their Function. Blood, 2016, 128, 2022: 654.
[18]
He, Kevin, SM Ali Hosseini Rad, Aarati Poudel, and Alexander Donald McLellan. "Compact bidirectional promoters for dual-gene expression in a Sleeping Beauty transposon." International journal of molecular sciences 21, no. 23, 2020: 9256.
[19]
Katchi, T., Liu, D. Diagnosis and treatment of CD20 negative B cell lymphomas. Biomark Res 5, 5, 2017. https://doi.org/10.1186/s40364-017-0088-5
[20]
Kogot-Levin, Aviram “Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts.” PloS one vol. 11,10 e0165417. 25, Oct., 2016.
[21]
Menk, Ashley V., Nicole E. Scharping, Dayana B. Rivadeneira, Michael J. Calderon, McLane J. Watson, Deanna Dunstane, Simon C. Watkins, and Greg M. Delgoffe. "4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses." Journal of Experimental Medicine 215, no. 4, 2018: 1091-1100.
[22]
Teijeira, Alvaro, Sara Labiano, Saray Garasa, Iñaki Etxeberria, Eva Santamaría, Ana Rouzaut, Michel Enamorado "Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation4-1BB (CD137) and Mitochondria." Cancer immunology research 6, no. 7, 2018: 798-811.
[23]
Wei, Shibo, Qing Fan, Liang Yang, Xiaodong Zhang, Yingbo Ma, Zhihong Zong, Xiangdong Hua "Promotion of glycolysis by HOTAIR through GLUT1 upregulation via mTOR signaling." Oncology Reports 38, no. 3, 2017: 1902-1908.
Index Terms
- Non-Hodgkin Lymphoma CAR T Cells: Enhancement on Synnotch Signaling, GLUT1 expression, and PGC1a expression brings Potential Clinical Advancement in Therapy
Index terms have been assigned to the content through auto-classification.
Recommendations
Identification of SLC2A1 as a predictive biomarker for survival and response to immunotherapy in lung squamous cell carcinoma
Abstract BackgroundAs one of the common subtypes of non-small lung cancer, lung squamous cell carcinoma (LUSC) patients with advanced stage have few choices of treatment strategies. Therefore, it is urgent to discover genes that are associated with the ...
Highlights- GLUT1 (SLC2A1) was differentially expressed between tumor and normal tissues, and an independent prognostic factor for LUSC patients.
- Higher SLC2A1 expression was associated with the abundance of SPP1+macrophage, and upregulation of ...
IL-18 expression in clinical human pituitary adenoma
Selected Papers From the 13th International Conference BIOMDLORE 2021BACKGROUND:IL-18 is known as an interferon-inducing factor that belongs to the IL-1 family, and is synthesized as an inactive precursor protein.
OBJECTIVE:The present study aims to investigate ...
Comments
Information & Contributors
Information
Published In
October 2022
594 pages
ISBN:9781450398442
DOI:10.1145/3570773
Copyright © 2022 ACM.
Permission to make digital or hard copies of all or part of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for components of this work owned by others than ACM must be honored. Abstracting with credit is permitted. To copy otherwise, or republish, to post on servers or to redistribute to lists, requires prior specific permission and/or a fee. Request permissions from [email protected]
Publisher
Association for Computing Machinery
New York, NY, United States
Publication History
Published: 09 December 2022
Check for updates
Author Tags
Qualifiers
- Research-article
- Research
- Refereed limited
Conference
ISAIMS 2022
ISAIMS 2022: 2022 3rd International Symposium on Artificial Intelligence for Medicine Sciences
October 13 - 15, 2022
Amsterdam, Netherlands
Acceptance Rates
Overall Acceptance Rate 53 of 112 submissions, 47%
Contributors
Other Metrics
Bibliometrics & Citations
Bibliometrics
Article Metrics
- 0Total Citations
- 52Total Downloads
- Downloads (Last 12 months)18
- Downloads (Last 6 weeks)8
Reflects downloads up to 15 Jan 2025
Other Metrics
Citations
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Sign inFull Access
View options
View or Download as a PDF file.
PDFeReader
View online with eReader.
eReaderHTML Format
View this article in HTML Format.
HTML Format